Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Staszewski

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
AIDS (London, England)|January 12, 2001
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failureV Miller, C Sabin, K Hertogs, et al.
AIDS (London, England)|June 10, 1998
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitorsV Miller, M Stürmer, S Staszewski, et al.
European Journal of Medical Research|April 17, 1999
Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF)A Stoehr, K Arasteh, S Staszewski, et al.
Antimicrobial Agents and Chemotherapy|August 3, 1999
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistanceB A Larder, S Bloor, S D Kemp, et al.
The New England Journal of Medicine|December 22, 1999
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 TeamS Staszewski, J Morales-Ramirez, K T Tashima, et al.
European Journal of Medical Research|May 18, 2007
Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patientsB Salzberger, M Däumer, P Gute, et al.
AIDS (London, England)|May 1, 1996
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patientsS Staszewski, V Miller, S Rehmet, et al.
Antiviral Therapy|January 1, 1996
Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study GroupS Staszewski, V Miller, A Kober, et al.
JAMA|March 20, 2001
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trialS Staszewski, P Keiser, J Montaner, et al.
European Journal of Medical Research|May 11, 2010
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive IndividualsM Vogel, G Ahlenstiel, B Hintsche, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|January 12, 2001
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failureV Miller, C Sabin, K Hertogs, et al.
AIDS (London, England)|June 10, 1998
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitorsV Miller, M Stürmer, S Staszewski, et al.
European Journal of Medical Research|April 17, 1999
Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF)A Stoehr, K Arasteh, S Staszewski, et al.
Antimicrobial Agents and Chemotherapy|August 3, 1999
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistanceB A Larder, S Bloor, S D Kemp, et al.
The New England Journal of Medicine|December 22, 1999
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 TeamS Staszewski, J Morales-Ramirez, K T Tashima, et al.
European Journal of Medical Research|May 18, 2007
Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patientsB Salzberger, M Däumer, P Gute, et al.
AIDS (London, England)|May 1, 1996
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patientsS Staszewski, V Miller, S Rehmet, et al.
Antiviral Therapy|January 1, 1996
Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study GroupS Staszewski, V Miller, A Kober, et al.
JAMA|March 20, 2001
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trialS Staszewski, P Keiser, J Montaner, et al.
European Journal of Medical Research|May 11, 2010
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive IndividualsM Vogel, G Ahlenstiel, B Hintsche, et al.
Pageof 10